Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.

Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS.

Oncotarget. 2016 Jun 21;7(25):38359-38366. doi: 10.18632/oncotarget.9521.

2.

Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity.

LaCroix B, Gamazon ER, Lenkala D, Im HK, Geeleher P, Ziliak D, Cox NJ, Huang RS.

BMC Genomics. 2014 Apr 16;15:292. doi: 10.1186/1471-2164-15-292.

3.

Integrative "omic" analysis for tamoxifen sensitivity through cell based models.

Weng L, Ziliak D, Lacroix B, Geeleher P, Huang RS.

PLoS One. 2014 Apr 3;9(4):e93420. doi: 10.1371/journal.pone.0093420. eCollection 2014.

4.

Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation.

Weng L, Ziliak D, Im HK, Gamazon ER, Philips S, Nguyen AT, Desta Z, Skaar TC; Consortium on Breast Cancer Pharmacogenomics (COBRA), Flockhart DA, Huang RS.

Ann Oncol. 2013 Jul;24(7):1867-73. doi: 10.1093/annonc/mdt125. Epub 2013 Mar 18.

5.

Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.

Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS.

Mol Cancer Ther. 2012 Sep;11(9):2054-61. doi: 10.1158/1535-7163.MCT-12-0221. Epub 2012 Jun 29.

6.

Genetic architecture of microRNA expression: implications for the transcriptome and complex traits.

Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, Cox NJ, Huang RS.

Am J Hum Genet. 2012 Jun 8;90(6):1046-63. doi: 10.1016/j.ajhg.2012.04.023. Epub 2012 May 31.

7.

Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.

Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Dolan ME.

Clin Cancer Res. 2011 Aug 15;17(16):5490-500. doi: 10.1158/1078-0432.CCR-11-0724. Epub 2011 Jun 24.

8.

Population differences in microRNA expression and biological implications.

Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME.

RNA Biol. 2011 Jul-Aug;8(4):692-701. doi: 10.4161/rna.8.4.16029. Epub 2011 Jul 1.

9.

Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.

Wen Y, Gorsic LK, Wheeler HE, Ziliak DM, Huang RS, Dolan ME.

Pharmacogenet Genomics. 2011 Aug;21(8):476-88. doi: 10.1097/FPC.0b013e3283481967.

10.

Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.

Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS.

Transl Res. 2011 May;157(5):265-72. doi: 10.1016/j.trsl.2011.01.005. Epub 2011 Feb 8.

11.

Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity.

Gamazon ER, Im HK, O'Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS.

Mol Cancer Ther. 2011 Mar;10(3):472-80. doi: 10.1158/1535-7163.MCT-10-0910. Epub 2011 Jan 20.

Supplemental Content

Loading ...
Support Center